Furthermore, WKYMVm treatment did not reduce the numbers of Vimentin+ or Vimentin+p-SMAD3+ myofibroblasts in the scleroderma skin of Fpr2 KO mice, in contrast to the significant inhibition of those in the scleroderma skin of wild type mice (Figures 6B,D,E). The gene discussed is FPR2; the disease is scleroderma.